Doxorubicin-Induced Thymus Senescence
详细信息 查看全文
- 作者：Rukhsana Sultana ; Fabio Di Domenico ; Michael Tseng ; Jian Cai ; Teresa Noel ; R. Lakshman Chelvarajan ; William D. Pierce ; Ciara Cini ; Subbarao Bondada ; Daret K. St. Clair ; D. Allan Butterfield
- 刊名：Journal of Proteome Research
- 出版年：2010
- 出版时间：December 3, 2010
- 年：2010
- 卷：9
- 期：12
- 页码：6232-6241
- 全文大小：414K
- 年卷期：v.9,no.12(December 3, 2010)
- ISSN：1535-3907
文摘
Doxorubicin (DOX) is an anticancer drug used for the treatment of solid tumors. The ability of DOX to treat cancer is not specific to cancer cells; some of the cells that are normal may also become targets of DOX, thereby altering the normal cellular functions and eventual cell loss. DOX effects have been studied in detail in heart because of its ability to cause cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy is not completely understood. One of organs that can be affected by DOX is thymus. DOX treatment leads to degeneration of thymus; however, since thymus undergoes age-dependent degeneration, researchers have understudied the effect of DOX on thymus. In the present investigation, we studied the effects of DOX on thymus, an organ that is important for the T-cell maturation. DOX treatment led to loss of cortical cells, decrease lymphopoiesis and increased the number of Hassells corpuscles, a marker of thymus aging. Proteomics analysis led to identification of a number of thymic proteins whose expression are altered by in vivo DOX treatment. Taken together, these results are consistent with the notion that DOX-treatment leads to thymic senescence.